Alleye
Smart screening and monitoring of retinal diseases
Due to demographic changes, the demand for ophthalmological services in old age is increasing. However, ophthalmologists are overburdened in many places and lack the time for valuable personal interactions with patients.
In cooperation with ophthalmologists, medignition developed the Alleye Platform. This mobile app detects retinal diseases before those affected even notice that there is a problem. Due to the early detection, Alleye enables an efficient treatment. Alleye also helps patients with an existing retinal disease to monitor the course of the disease. The Alleye values are transmitted to the treating ophthalmologist in real time and are available to the physician via an intuitive web application. Remote monitoring allows ophthalmologists to focus on those patients who need or want personal interaction.
medignition is co-founder of Oculocare medical AG, which distributes Alleye. medignition has conducted clinical research, ISO certification, FDA approval, patient data protection and overall development of the digital platform for Oculocare. medignition was also driving the international patenting of Alleye and designed its corporate identity.
Due to demographic changes, the demand for ophthalmological services in old age is increasing. However, ophthalmologists are overburdened in many places and lack the time for valuable personal interactions with patients.
In cooperation with ophthalmologists, medignition developed the Alleye Platform. This mobile app detects retinal diseases before those affected even notice that there is a problem. Due to the early detection, Alleye enables an efficient treatment. Alleye also helps patients with an existing retinal disease to monitor the course of the disease. The Alleye values are transmitted to the treating ophthalmologist in real time and are available to the physician via an intuitive web application. Remote monitoring allows ophthalmologists to focus on those patients who need or want personal interaction.
medignition is co-founder of Oculocare medical AG, which distributes Alleye. medignition has conducted clinical research, ISO certification, FDA approval, patient data protection and overall development of the digital platform for Oculocare. medignition was also driving the international patenting of Alleye and designed its corporate identity.
>90%
of retinal diseases are correctly detected by Alleye
4
countries have granted a patent for Alleye (China, Japan, Russia, USA)
>100k
Alleye tests performed since 2017
>2000
patients use Alleye to monitor retinal diseases
ISO
certified for the distribution of medical devices
FDA
approved by the American health authority (510k)